BRPI1014858A2 - "antagonistas de bmp-alk3 e usos para promover o crescimento ósseo" - Google Patents

"antagonistas de bmp-alk3 e usos para promover o crescimento ósseo"

Info

Publication number
BRPI1014858A2
BRPI1014858A2 BRPI1014858A BRPI1014858A BRPI1014858A2 BR PI1014858 A2 BRPI1014858 A2 BR PI1014858A2 BR PI1014858 A BRPI1014858 A BR PI1014858A BR PI1014858 A BRPI1014858 A BR PI1014858A BR PI1014858 A2 BRPI1014858 A2 BR PI1014858A2
Authority
BR
Brazil
Prior art keywords
bmp
bone growth
promote bone
alk3 antagonists
alk3
Prior art date
Application number
BRPI1014858A
Other languages
English (en)
Inventor
Seehra Jasbir
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42828671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1014858(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of BRPI1014858A2 publication Critical patent/BRPI1014858A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI1014858A 2009-03-30 2010-03-30 "antagonistas de bmp-alk3 e usos para promover o crescimento ósseo" BRPI1014858A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21155709P 2009-03-30 2009-03-30
US30633110P 2010-02-19 2010-02-19
US31455610P 2010-03-16 2010-03-16
PCT/US2010/029282 WO2010114860A1 (en) 2009-03-30 2010-03-30 Bmp-alk3 antagonists and uses for promoting bone growth

Publications (1)

Publication Number Publication Date
BRPI1014858A2 true BRPI1014858A2 (pt) 2017-03-28

Family

ID=42828671

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014858A BRPI1014858A2 (pt) 2009-03-30 2010-03-30 "antagonistas de bmp-alk3 e usos para promover o crescimento ósseo"

Country Status (10)

Country Link
US (5) US8338377B2 (pt)
EP (4) EP3384964B1 (pt)
JP (6) JP5755635B2 (pt)
KR (2) KR101805201B1 (pt)
CN (2) CN102548617B (pt)
AU (4) AU2010232693B2 (pt)
BR (1) BRPI1014858A2 (pt)
CA (1) CA2757095C (pt)
ES (1) ES2575695T3 (pt)
WO (1) WO2010114860A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548617B (zh) 2009-03-30 2017-11-07 阿塞勒隆制药公司 Bmp‑alk3拮抗剂和促进骨生长的用途
EP3549952A1 (en) 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
KR101421171B1 (ko) 2011-08-31 2014-07-22 재단법인 제이씨비 공동생물과학연구소 인간 골형성 단백질 수용체 1ａ의 세포외 도메인을 유효성분으로 포함하는 피부 상태 개선용 조성물
WO2013032248A2 (ko) * 2011-08-31 2013-03-07 재단법인 제이씨비 공동생물과학연구소 인간 골형성 단백질 수용체 1ａ의 세포외 도메인을 유효성분으로 포함하는 피부 상태 개선용 조성물
EP2844668A1 (en) 2012-05-03 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
HK1225742A1 (zh) * 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
AU2014339898B2 (en) * 2013-10-25 2020-07-23 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
WO2016144917A1 (en) 2015-03-10 2016-09-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
EP3280435B1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
JP2016204292A (ja) * 2015-04-21 2016-12-08 国立大学法人 熊本大学 Ｂｍｐ７変異体とアルブミンとの融合体、及び該融合体を含む腎疾患治療剤
CN105254764A (zh) * 2015-08-27 2016-01-20 上海康岱生物医药技术有限公司 ACVR1-Fc融合蛋白及其制法和用途
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
WO2018053234A1 (en) 2016-09-15 2018-03-22 Acceleron Pharma, Inc. Twisted gastrulation polypeptides and uses thereof
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
WO2020090705A1 (ja) 2018-10-31 2020-05-07 千寿製薬株式会社 網膜神経節細胞死抑制剤
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
KR20230066044A (ko) * 2020-09-10 2023-05-12 샨시 마이콧 테크놀로지 컴퍼니 리미티드 이중특이적 융합 폴리펩타이드 화합물
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022240948A1 (en) * 2021-05-11 2022-11-17 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
NZ257631A (en) 1992-11-17 1996-03-26 Ludwig Inst Cancer Res Serine/threonine kinase domain-containing protein, dna and hosts therefor
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6248554B1 (en) 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
EP0756628B1 (en) 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
JPH07313169A (ja) 1994-05-26 1995-12-05 Nippon Ham Kk 骨形成因子受容体改変体の遺伝子
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
WO2000018895A1 (en) 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2001053455A2 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US6630304B1 (en) 2000-09-14 2003-10-07 Decode Genetics Ehf. Human osteoporosis gene
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
AU2003261246A1 (en) 2002-08-16 2004-03-03 Wyeth Bmp-2 estrogen responsive element and methods of using the same
CN1835974A (zh) * 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
CA2587424A1 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
BRPI0616589A2 (pt) * 2005-09-28 2011-06-28 Zymogenetics Inc polipeptìdeo, e, métodos para produzir um anticorpo para um polipeptìdeo, para reduzir ou inibir a inflamação e para tratar um mamìfero afligido com uma doença inflamatória
ES2353117T3 (es) * 2005-09-28 2011-02-25 Zymogenetics, Inc. Antagonistas de il-17a e il-17f y métodos de uso de los mismos antagonistas de il-17a e il-17f y métodos de uso de los mismos.
BRPI0618947B1 (pt) * 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
CN112457389A (zh) * 2005-11-23 2021-03-09 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
WO2009025651A1 (en) * 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
CN102548617B (zh) 2009-03-30 2017-11-07 阿塞勒隆制药公司 Bmp‑alk3拮抗剂和促进骨生长的用途

Also Published As

Publication number Publication date
EP2414043A1 (en) 2012-02-08
CN107970445A (zh) 2018-05-01
EP2414043A4 (en) 2012-10-24
EP2414043B1 (en) 2016-01-13
CA2757095C (en) 2020-04-14
JP2019146568A (ja) 2019-09-05
AU2010232693A1 (en) 2011-11-03
KR101805201B1 (ko) 2017-12-05
CN107970445B (zh) 2021-09-07
EP3384964B1 (en) 2020-03-25
AU2020204120A1 (en) 2020-07-09
JP5755635B2 (ja) 2015-07-29
US20150266941A1 (en) 2015-09-24
CN102548617A (zh) 2012-07-04
JP2021036916A (ja) 2021-03-11
JP2012522507A (ja) 2012-09-27
US9914762B2 (en) 2018-03-13
AU2018201132A1 (en) 2018-03-08
JP2017153478A (ja) 2017-09-07
EP3058986B1 (en) 2018-05-09
US20180305438A1 (en) 2018-10-25
US20220127330A1 (en) 2022-04-28
EP3384964A1 (en) 2018-10-10
JP2022048160A (ja) 2022-03-25
ES2575695T3 (es) 2016-06-30
KR20120034604A (ko) 2012-04-12
JP2015157856A (ja) 2015-09-03
US8945877B2 (en) 2015-02-03
KR20170134788A (ko) 2017-12-06
WO2010114860A1 (en) 2010-10-07
CN102548617B (zh) 2017-11-07
US8338377B2 (en) 2012-12-25
EP3702001A1 (en) 2020-09-02
AU2016204979A1 (en) 2016-08-04
US20100266612A1 (en) 2010-10-21
AU2018201132B2 (en) 2020-03-26
AU2010232693B2 (en) 2016-04-21
EP3058986A1 (en) 2016-08-24
US20130101603A1 (en) 2013-04-25
CA2757095A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
HRP20190137T1 (hr) Stabilne formulacije polipeptida i njihova uporaba
DK2473116T3 (da) Knoglevækstindretning
FR2934147B1 (fr) Implant d'osteosynthese vertebrale
BRPI1014522A2 (pt) composicoes e metodos para aumentar o crescimento muscular
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
BRPI1014864A2 (pt) "implante de processos espinhosos e métodos associados"
FR2944692B1 (fr) Materiel d'osteosynthese vertebrale
EP2414043A4 (en) BMP-ALK3 ANTAGONISTS AND THEIR USE TO PROMOTE BONE GROWTH
BRPI0920670A8 (pt) composição nutritiva para promover o desenvolvimento e crescimento sadios
FR2957244B1 (fr) Implant d'arthrodese
BRPI1013265A2 (pt) implante raquidiano
BR112012009021A2 (pt) dispositivo de cuidados para tecidos
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
EP2403434A4 (en) PATIENT-ADAPTED AND IMPROVED ORTHOPEDIC IMPLANTS, DESIGNS AND RELATED INSTRUMENTS
BRPI1008186A2 (pt) "aperfeiçoamentos do grampeador cirúrgico acionado"
DK2453939T3 (da) Knogleimplantater
BRPI1011710A2 (pt) lágrimas artificiais e usos trapêuticos
EP2490698A4 (en) MODULATION OF THE AXONDEGENERATION
EP2483210A4 (en) PREPARATION COMPOSITION WITH ALUMINUM SLUDGE
BR112013000705A2 (pt) "composição de limpeza para cuidado pessoal"
BR112012004448A2 (pt) "compostos e composições como inibidores de proteína cinase"
EP2866743A4 (en) ORTHOPEDIC PROSTHESIS WITH SEAM ANCHOR FUNCTIONS
BRPI1006024A2 (pt) composição cosmética emulsificada
BRPI0906058A2 (pt) "jarra para produtos cosméticos"
ZA201204521B (en) Beta-cell replication promoting compounds and methods of the their use

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements